Q1 2026 Natco Pharma Ltd Earnings Call Transcript
Key Points
- Natco Pharma Ltd (BOM:524816) recorded consolidated total revenue of INR1,390.6 crores for Q1 FY26, maintaining a stable revenue stream compared to the previous year.
- The company achieved an EBITDA of INR632.7 crores with strong margins at 45.5%, indicating efficient operational management.
- Natco Pharma Ltd declared an interim dividend of INR2 per equity share, reflecting a commitment to returning value to shareholders.
- The crop health sciences segment showed a good pickup with expectations to reach breakeven soon, indicating potential growth in this area.
- The company is diversifying its portfolio by acquiring a significant stake in a South African company, which is expected to contribute 15% to 25% of base earnings in the future.
- Natco Pharma Ltd faced pricing pressure in its US product portfolio, particularly with Revlimid, impacting overall profitability.
- Increased R&D expenses due to high-value projects led to higher other expenses for the quarter, affecting net profit margins.
- The net profit for the period was INR480.3 crores, showing a decline compared to the previous year due to erosion in the US business.
- The company anticipates a decline in Revlimid contributions post-September quarter, which could impact future earnings.
- There are ongoing regulatory challenges with the Kothur facility, which has multiple observations that need resolution.
Ladies and gentlemen, good day, and welcome to NATCO Pharma Limited Q1 FY26 post results earnings conference call hosted by B&K Securities India Private. Limited. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Hrishikesh from B&K Securities. Thank you, and over to you, sir.
Thank you. Good morning, everyone. On behalf of B&K Securities, I welcome you all to the Q1 FY26 earnings conference call of NATCO Pharma. Hope everyone is in good health and doing well. On behalf of NATCO today, we have with us Mr. Rajeev Nannapaneni, Vice Chairman and CEO; Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences.
I now hand over the call to Rajesh for the management's opening remarks, post which we'll open the session for Q&A. Over to you, sir.
Thank
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
